Lexington, MA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- DoubleRainbow Biosciences (“Double Rainbow”), a sustainable biotech company harnessing bioengineering to improve the quality of human health, announced today a new research collaboration with Kelai Pharmaceuticals (“Kelai”) to explore the potential of biosynthetic kavalactone therapeutics. Kelai will include one of Double Rainbow’s molecules in their ongoing cell transcriptome study. Additionally, the two organizations will pair Kelai’s patented advanced drug delivery systems with the leading plant natural product biosynthesis capabilities of Double Rainbow to explore new opportunities for sustainable therapeutics.
Today, as many as 1 billion people worldwide are living with mental or substance use disorders.i Kelai Pharmaceutical specializes in the development of advanced drug delivery (ADD) technologies that utilize natural compounds such as those found in Kava (Piper methysticum) to develop innovative therapies for people living with addiction, mental health disorders, and related conditions. Using Double Rainbow’s proprietary HARMONYTM platform, the companies will leverage synthetic biology to help Kelai unlock the potential of these natural compounds through sustainable biosynthetic production.
“Synthetic biology offers a solution that supports Kelai’s intentions. As a company, our mission includes doing no harm in the name of doing good,” remarks Dr Jacqueline Jacques, Chief Executive Officer of Kelai Pharmaceutical. “The supply chain for a natural molecule could be exhausted with the creation of even one new drug. It’s an honor to engage with Double Rainbow on some of our early science. We feel very aligned with their team and their vision, and we hope that this discovery process leads to bigger developments in the future.”
Kava (Piper methysticum) belongs to the pepper family of plants and is native to parts of the South Pacific. Kava has been used for centuries in traditional cultures throughout the South Pacific. The plant’s reported relaxing effect, without associated cognitive impairment, makes it an ideal candidate for further research. Several recent studies have explored the potential of Kava in Generalized Anxiety Disorder, showing observed clinical effectsii, but more work is needed to understand the full therapeutic potential of Kava-based therapeutics.
"It’s an honor to collaborate with partners such as Kelai who are working to use potent medicinal plants to meaningfully improve the quality of life for hundreds of millions of people living with mental or substance use disorders,” said Jing-Ke Weng, Co-founder of DoubleRainbow Biosciences. “At Double Rainbow, our goal is to leverage our technologies to pioneer the future of natural product bioengineering and create new opportunities to deliver safer, more effective therapies for patients around the world.”
HARMONYTM is a molecular biosynthesis platform that decodes the biosynthetic pathways of potent bioactive compounds and sustainably recreates them through synthetic biology. Double Rainbow is leveraging HARMONYTM to explore molecules across all kingdoms of life and revolutionize their global supply to create opportunities for sustainable use across pharmaceutical, nutraceutical, and commercial applications.
Nature is a tremendous source of bioactive compounds that offer a wide range of medicinal benefits. These compounds have been explored and utilized in traditional medicine for centuries and underpin many modern therapeutics; however, any research seeking to leverage these potent natural products for largescale distribution must recognize the increasing threats to the global supply of medicinal plants. In Europe alone, more than 31% of medicinal plants are in or near decline, according to the European Red List, with overcollection being one of the primary drivers.iii Collaborations between organizations like Double Rainbow and Kelai to create new, sustainable sources for these critical compounds are vital to protecting the long-term health and wellbeing of both people and the planet.
Double Rainbow is a sustainable biotech company harnessing the power of natural evolution through bioengineering to improve the quality of human health and ensure the sustainability of our planet. By leveraging advances in the areas of genomics, metabolomics, and synthetic biology we are accessing the richness and efficacy of natural chemistry like never before, to bring therapeutics to the world at scale without harming the environment. Learn more at www.doublerainbowbio.com
Kelai Pharmaceutical is a U.S.-based pharmaceutical company that brings together powerful natural molecules with patented Advanced Drug Delivery technology to create safe and effective new treatments for addiction and mental health disorders. As a strategic joint venture created by Thorne HealthTech and Mycrodose Therapeutics, Kelai leverages the resources, intellectual property, and human capital of both companies to focus on lean drug development and innovation for conditions with unmet or underserved needs. Learn more at www.KelaiPharma.com
i Rehm J, Shield KD. Global Burden of Disease and the Impact of Mental and Addictive Disorders. Curr Psychiatry Rep. 2019 Feb 7;21(2):10. doi: 10.1007/s11920-019-0997-0. PMID: 30729322.
ii Sarris, J., Kavanagh, D. J., Byrne, G., Bone, K. M., Adams, J., & Deed, G. (2009). The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology, 205(3), 399-407.
iii Summary of key findings. European Redlist — Environment — European Commission. (n.d.). Retrieved June 2, 2022, from https://ec.europa.eu/environment/nature/conservation/species/redlist/med_plants/summary.htm
One summer night, Misty Castillo stepped out of her house in Salem, Oregon, called 911 and asked for the police, saying her son was mentally ill, was assaulting her and her husband and had a knife. “He's drunk and he's high and he's mentally ill,” Castillo told the emergency dispatcher, emphasizing again her son's mental condition. Less than five minutes later, a police officer burst into the house and shot Arcadio Castillo III dead as he stood, his mother said later, "frozen like a deer in headlights.”
"She needed therapy more than I did."View Entire Post ›
(Bloomberg) -- Nomura Holdings Inc. pushed through hundreds of millions of dollars of trades for hedge fund Glen Point Capital LLP that are now at the center of US criminal charges against its co-founder Neil Phillips, according to people familiar with the matter. Most Read from BloombergGlobal Bonds Tumble Into Their First Bear Market in a GenerationLukoil Chairman Ravil Maganov Dies After Falling From Hospital WindowStocks Suffer Third Weekly Loss on Rate-Hike Woes: Markets WrapPutin Brings Ch
The U.S. dollar is on a tear, hitting historic highs against major rivals. Here's how that could add to market volatility.
Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.
ConocoPhillips CEO Ryan M. Lance purchased a large block of shares of copper miner Freeport-McMoRan, which he serves as a director.
Style Box ETF report for IWX
After losing some value lately, a hammer chart pattern has been formed for Applied Therapeutics Inc. (APLT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Warren Buffett’s initial $232 million investment has returned over $7 billion—so far.
Softbank Group Corp. is planning to cut at least 100 jobs or 20% of its staff at the technology firm's Vision Fund, Bloomberg reported Friday. Citing people familiar with the firm, the news service reported the positions will be reduced in the U.S., China and the U.K. The moves come after founder Masayoshi Son said he would carry out job cuts at the technology investment firm. Last month, Softbank disclosed its Vision Fund surrendered about $40 billion in gains in the year ended June 30. U.S.-li
(Bloomberg) -- Armando Mejia Sanchez, the head of crude oil at the trading arm of Mexico’s state-owned oil firm Pemex, is retiring, according to people with knowledge of the situation.Most Read from BloombergJeremy Grantham Warns ‘Super Bubble’ in Stocks Has Yet to BurstTrump Documents Bear Hallmarks of Closest-Held US SecretsJapan to Allow Non-Guided Group Tours From SeptemberPowell Abandons Soft Landing Goal as He Seeks Growth RecessionPutin Brings China and India to Russia for War Games Defyi
A number of franchisors disclose how much money their highest-earning franchisee-owned locations make. Here's a look at some of the bigger Minnesota-based franchisors and how much they say a franchisee can make.
Leading Payments Platform Developed For Architects Provides Vital Benefits to AIA Members And AEC Industry Professionals
Electrification of the roads appears to have tremendous potential not just for Toyota, but for builders, workers, suppliers and governments in the Triad. Toyota’s announcement Wednesday morning that it was more than doubling its investment in its vehicle battery plant at the Greensboro-Randolph Megasite to $3.8 billion from the previously planned $1.29 billion means that much more to go around in Randolph and Guilford counties and surrounding communities. One part of the government incentive package used to lure Toyota in December was a plan for Randolph County to reimburse the company 60% of tax payments over 20 years.
The first part of the merge, dubbed the Bellatrix upgrade, will take place on Sept. 6. And independent researcher and artist Kyle McDonald argues that after the merge, investors and regulators are going to realize that proof-of-work was never really necessary.
Dan Niles, a money manager who has been bearish on the stock market, is even more pessimistic now. But he does see some opportunities, including in shares of Walmart and Amazon.com.
(Reuters) -Johnson & Johnson has agreed to pay $40.5 million to settle New Hampshire's claims over the company's role in the U.S. opioid epidemic, averting a trial that had been scheduled to begin next week. Thursday's settlement resolves a lawsuit brought in 2018 against Johnson & Johnson and its Janssen Pharmaceuticals unit. New Hampshire accused them of aggressively marketing opioids to doctors and patients, misrepresenting their addictive properties when used to treat chronic pain, and targeting vulnerable groups like the elderly.
The U.S. dollar soared versus major rivals Thursday, boosted by resilient data on weekly jobless claims and a gauge of manufacturing activity that affirmed expectations the Federal Reserve will continue aggressively tightening monetary policy in its bid to get a grip on inflation. The dollar was up 0.7% veruss the Japanese currency at 139.93 yen after trading as high as 140.23 --- its highest since August 1998, according to FactSet. The euro slumped 1.2% to fetch 99.37 U.S. cents. Meanwhile, the
Shares of Signet Jewelers Ltd. surged 2.5% in premarket trading Thursday, after the diamond jewelry retailer reported fiscal second-quarter profit that beat expectations and sales that matched, while affirming its upbeat full-year outlook. Net income for the quarter to July 30 fell to $136.8 million, or $2.58 a share, from $216.0 million, or $3.60 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of $2.68 beat the FactSet consensus of $2.59. Sales slipped
The auto maker reported a fourfold surge in electric-vehicle sales amid strong interest in its all-electric F-150 Lightning truck.